Table 3 Cyclin D1 and p27 tumor expression in the pre-treatment setting
Patients completed all study parts | n = 42 |
|---|---|
Cyclin D1 nuclear fraction (n = 30) | |
Negative | 2 (7%) |
Low (1-50%) | 12 (40%) |
High (51-100%) | 16 (53%) |
Cyclin D1 nuclear intensity (n = 30) | |
Negative | 2 (7%) |
Weak | 5 (12%) |
Moderate | 14 (33%) |
Strong | 9 (30%) |
Cyclin D1 cytoplasmic intensity (n = 30) | |
Negative | 11(37%) |
Weak | 14 (47%) |
Moderate | 2 (7%) |
Strong | 3 (10%) |
p27 nuclear fraction (n = 33) | |
Negative | 0 |
Low (1-50%) | 8 (24%) |
High (51-100%) | 25 (76%) |
p27 nuclear intensity (n = 33) | |
Negative | 0 |
Weak | 3 (9%) |
Moderate | 18 (55%) |
Strong | 12 (36%) |
p27 cytoplasmic intensity (n = 33) | |
Negative | 17 (52%) |
Weak | 14 (42%) |
Moderate | 2 (6%) |
Strong | 0 |